Friday, February 20, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Politics & Law

Marijuana-Opioid Switcheroo

When substitutions pass as solutions

Daily Remedy by Daily Remedy
October 16, 2022
in Politics & Law
0
Marijuana-Opioid Switcheroo

Amazing how many alleged solutions just substitute one problem for another. Take President Biden’s recent move to pardon those with federal convictions for simple marijuana possession.

Though the move is symbolic as most marijuana convictions are at the state level, it speeds up a trend that has been going on for years: Decriminalize drugs and regulate its use both medically and recreationally – just like marijuana.

It follows public sentiment. It has the approval of most politicians. And it seems like a major step in advancing the country’s drug policy for the modern century. But taking one step doesn’t mean we know where we’re going.

The mass pardoning ostensibly decriminalizes and de-stigmatizes marijuana. The move would seem to make it more accessible to the public. But we are still uncertain of its implications for broader drug policy. There remain more unknowns than knowns, but we only care to look at what is most obvious.

Increasing access to marijuana is certainly a bellwether. It could lead to further decriminalization, or it could lead to reflexive restrictions on other medications with addictive potential. The public sees the decriminalization of marijuana as the start of initiatives to decriminalize other substances.

The powers that be see it as the latter. Policy makers see marijuana as a substitute for other more harmful substances, like prescription opioids. In decriminalizing marijuana, they suggest that those with dependencies or addictions would be better off using marijuana instead of opioids. There are plenty of studies supporting either stance, but there are few data objectively clarifying which is truly better for patients. When it comes to drug policy, most clinical studies use data as a pretense for preconceived beliefs. It’s hard to know what to believe.

But we know what policy makers think. They see access as an opportunity cost. By increasing access to marijuana, they imply we should decrease access to other substances.

This is the bait and switch. It belies the disconnect between policy makers and the public. The public thinks policy makers will follow the will of the public. But the two sides have different perspectives on drug policy.

The mass pardoning of marijuana doesn’t change our overall stance on drugs and access, it changes our perspective on marijuana relative to other medications and illicit opioids. The public thinks the two align, but policy makers see the two as opposites.

To get this, we must look at the issues beyond the superficial headlines. In the coming months, we will see newfound restrictions on opioids, whether that is as prescription quotas or more punitive sentencing measures for illicit substance possession.

When it happens, the public will be shocked. But we should have known better. This is a repeated pattern in the Government’s war on drugs. It strikes at the heart of the divide between central control and personal liberties. Policy makers want one policy, the public wants individual choice.

When we enact broad policy over a swath of diverse communities, the effects will be mixed, varying relative to the make-up and predisposition of each community. It’s natural to think each person should make their own decisions. But this is the inevitable tension that arises when thinking individually versus enacting broad policy.

But we cannot grasp these critical tensions. The public who advocates for harm reduction will see this as the start of a trend towards further decriminalization. Policy makers who have more traditional views on drugs, the war on drug true-believers, will see this as a negotiation, a move to allow access to marijuana in exchange for additional restrictions on other substances – a veritable prison exchange of substances.

But one general policy for all drug use, a prescriptive approach to drug policy, is not the right way. We need to look at drug policy through a medical lens. See those who use substances, or are inclined to opioid abuse, as patients. Patient care is best when it is individualized to each person. Similarly, drug policy is best when it caters to the unique needs of each community. So let communities decide for themselves what drug policy works best for them.

Funny thing about drugs in America is that no one wants to leave the other alone. We have a habit of moralizing our view on others, and when people disagree, we vilify them. This naturally leads to antagonistic views on drug policy and an inevitable polarization.

President Biden simply added fuel to the fire. He created more problems than fix much of anything. The mass pardons ignited a debate that will lead to an inevitable polarization of marijuana relative to other substances with dependency potential: is marijuana a substitute for more dangerous drugs or a harbinger of greater access to drugs overall.

Pick one. It can’t be both. The policy makers have already decided.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Comments 0

  1. Chuck Gartland says:
    3 years ago

    Not sure I agree that this nebulous group of policymakers has decided as you opine, but I enjoyed this article. I am a proponent of legalization and regulation for all drugs. For starters that essentially ends fatal OD as one will know exactly what one is using. Thanks for covering this topic

    Reply
    • Linda Cheek MD says:
      3 years ago

      Please join my room on Clubhouse, a phone-based social media, called End the War on Drugs. No drug causes addiction. The propaganda that they do is because it provides jobs and money for the government, but now more money is going down the drain following policies that are expensive and will do nothing to end the problem. Only learning what I teach will end the problem, and that will be up to the individual person, as it is a lifestyle change. You can learn how to get on Clubhouse here: https://doctorsofcourage.org/invitation-to-clubhouse/. We had our first session yesterday, with a great turnout. We will continue meeting on Tuesdays at 2PM ET. As the following grows, I will add more rooms at different times. This is a fantastic way to spread the word that drugs are not the cause and that the attack on drugs is purely political and anit-minority, for discrimination purposes.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • The Staffing Equation That Doesn’t Balance

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy